Browse the evidence

Survodutide, a dual glucagon and GLP-1 receptor agonist, produces significant weight loss, BMI reduction, and waist circumference reduction in adults with overweight or obesity.

Survodutide is a once-weekly injection that significantly reduces weight, BMI, and waist size. The benefits are greater with higher doses (>2mg/week) and longer treatment durations (>16 weeks). It is particularly effective for individuals under 50 years old. Common side effects are gastrointestinal, but it offers a non-surgical option for weight management.

The efficacy of Survodutide for weight loss is conditional on dose and duration, with doses >2 mg/week and interventions >16 weeks yielding significantly greater reductions in weight and waist circumference.

To maximize weight loss with Survodutide, ensure you are on a dose above 2 mg/week and continue treatment for at least 16 weeks. Lower doses or shorter durations result in less significant weight and waist circumference reduction.

Weekly subcutaneous administration of Tirzepatide (5-15 mg) significantly reduces body weight and body fat percentage in non-diabetic obese patients compared to placebo, with effects comparable to bariatric surgery.

If you are obese and non-diabetic, Tirzepatide is a highly effective weekly injection that can lead to significant weight loss (up to ~21%) and fat loss, outperforming previous GLP-1 drugs. It requires a commitment to weekly injections and lifestyle changes (diet and 150 mins/week exercise), but may offer a better side-effect profile regarding nausea than older drugs due to its dual GIP/GLP-1 mechanism.

A once-weekly synthetic semaglutide formulation (test drug) provides weight loss efficacy and safety comparable to the innovator semaglutide (Wegovy) in Indian adults with obesity over a 24-week period.

If you are an adult in India with obesity who has struggled to lose weight through diet and exercise alone, this study shows that a once-weekly synthetic semaglutide injection works just as well as the brand-name version (Wegovy) over 24 weeks. You can expect to lose about 14-15% of your body weight if you follow the dose-titration schedule (starting low and increasing every 4 weeks) alongside a 500-calorie daily deficit and 150 minutes of weekly exercise. While you may experience common side effects like nausea or constipation, they are generally mild and manageable. This option may be more affordable than the brand name, making it a viable long-term management tool.

Tirzepatide (5 mg, 10 mg, and 15 mg) significantly reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 receptor agonists, and basal insulin.

Tirzepatide is a highly effective treatment for weight loss in people with T2DM or obesity, outperforming other common medications like GLP-1 agonists and insulin. It is taken as a once-weekly injection. While it causes gastrointestinal side effects like nausea and diarrhea, these are usually mild and temporary. If you are considering this, discuss the benefits of significant weight loss against the potential for temporary stomach issues with your doctor.

Subcutaneous Tirzepatide significantly reduces body weight, BMI, and waist circumference in adults with obesity or type 2 diabetes compared to placebo.

If you have obesity or type 2 diabetes and lifestyle changes haven't been enough, Tirzepatide is a highly effective, once-weekly injection that significantly reduces weight, BMI, and waist circumference. The effect is dose-dependent, with higher doses (up to 15mg) yielding greater weight loss. Be prepared for potential gastrointestinal side effects like nausea, which are common but often manageable.

In real-world clinical practice, tirzepatide produces significantly greater weight loss and higher rates of achieving clinically meaningful weight loss thresholds (≥5%, ≥10%, ≥15%) compared to semaglutide in adults with overweight or obesity.

If you are using tirzepatide (Mounjaro) or semaglutide (Ozempic) for weight loss, real-world data suggests that tirzepatide is more effective at helping you lose significant amounts of weight (10% or more of your body weight) compared to semaglutide. You are also more likely to reach these milestones faster with tirzepatide. However, both drugs carry similar risks of gastrointestinal side effects, so tolerability is a key factor in choosing between them.

Tirzepatide produces significantly greater weight loss than semaglutide in adults with obesity or overweight, with the magnitude of loss increasing with higher doses (>10 mg) and longer treatment durations (>6 months).

If you are using semaglutide and not achieving your weight loss goals, switching to tirzepatide (particularly at doses above 10 mg and continuing for more than 6 months) is likely to result in significantly greater weight loss. The data supports tirzepatide as a more potent option for reducing body weight compared to semaglutide.

Weekly administration of semaglutide at 2.4 mg induces significant weight loss (mean 14.9%) and improves glycemic control (HbA1c < 7.0% in 57-74% of patients) in adults with obesity or type 2 diabetes, with effects proportional to dose and duration.

If you have obesity or type 2 diabetes, weekly semaglutide (2.4 mg for weight loss, 1-1.0 mg for diabetes) is a highly effective treatment that can lead to significant weight loss (up to 15%) and better blood sugar control. While nausea and vomiting are common side effects, they are usually mild and temporary, and weight loss often occurs regardless of whether you experience them. An oral version is also available if you prefer to avoid injections. Discuss this with your doctor to see if it's right for you.

Tirzepatide produces significantly greater weight loss than semaglutide in overweight and obese adults, with a standardized mean difference of 0.75 favoring tirzepatide.

If you are choosing between tirzepatide and semaglutide for weight loss, current direct comparative evidence suggests tirzepatide may lead to greater weight reduction. This benefit comes with a dual-hormone mechanism (GIP/GLP-1) and requires weekly injections. You should expect potential gastrointestinal side effects during dose increases, which are usually manageable. Combining the medication with diet and exercise will likely enhance results.

Tirzepatide significantly increases the odds of achieving clinically meaningful weight loss (≥10% body weight reduction) compared to semaglutide.

A key benefit of tirzepatide over semaglutide is the increased likelihood of losing 10% or more of your body weight, a threshold often associated with significant health improvements. This makes tirzepatide a potentially more effective option if your primary goal is substantial weight reduction. Discuss with your provider whether this higher efficacy profile aligns with your health goals.

Oral semaglutide (50 mg once daily) is effective for weight loss in non-diabetic obese/overweight adults, though generally less effective than the subcutaneous 2.4 mg formulation.

If you prefer not to use injections, oral semaglutide (50 mg daily) is a viable option for weight loss in non-diabetic adults with obesity. It produces significant weight loss (average 15%), though it requires daily adherence. It is generally considered less effective than the weekly injectable form, so discuss with your provider which form best fits your lifestyle and medical needs.

Subcutaneous semaglutide 2.4 mg once weekly produces 15–17% mean weight loss and offers cardioprotection in obesity treatment.

If you have obesity, subcutaneous semaglutide 2.4 mg once weekly is an approved treatment that can help you lose 15–17% of your body weight and may protect your heart. This is significantly more effective than lifestyle changes alone, which often fail to maintain weight loss long-term.

Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves up to 22.5% mean weight loss in phase 3 obesity trials.

Tirzepatide is a dual-acting hormone medication (GLP-1/GIP) that can lead to up to 22.5% weight loss in clinical trials, surpassing single-agonist GLP-1 drugs. It is available for obesity management.

Oral semaglutide 50 mg once daily results in 17.4% weight loss in people with obesity without type 2 diabetes.

For those who prefer not to inject medication, oral semaglutide 50 mg once daily can achieve 17.4% weight loss in people with obesity without diabetes, comparable to the injectable version.

Survodutide, a dual glucagon/GLP-1 receptor agonist, produces dose-dependent reductions in HbA1c and bodyweight in people with type 2 diabetes, with doses ≥1.8 mg once weekly yielding greater bodyweight loss than semaglutide 1.0 mg.

For individuals with type 2 diabetes seeking significant weight loss and glucose control, dual GLP-1/GCGR agonists like survodutide offer superior bodyweight reduction compared to standard GLP-1 therapies like semaglutide, particularly at doses of 1.8 mg/week or higher. Expect gastrointestinal side effects, which can be managed by starting with lower doses and escalating slowly.

Once-weekly subcutaneous administration of GLP-1R/GIPR dual agonist tirzepatide (up to 15 mg/week) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with efficacy exceeding current GLP-1RAs.

If you have type 2 diabetes and struggle with weight, ask your doctor about tirzepatide. It is a once-weekly injection that has been shown to lower blood sugar and reduce body weight more effectively than older GLP-1 drugs. While injections can be a barrier, oral options exist for other drugs in this class.

Combining the amylin analogue cagrilintide (4.5 mg/week) with semaglutide (2.4 mg/week) results in greater weight loss (15.4% reduction) than either agent alone in obese or overweight individuals.

For significant weight loss, combining cagrilintide and semaglutide has shown a 15.4% body weight reduction in 20 weeks. This combination therapy is an option for those who do not achieve sufficient weight loss with single-agent GLP-1 therapy.

Insufficient or fragmented sleep reduces skeletal muscle protein synthesis rates and promotes a catabolic hormonal environment (elevated cortisol, reduced testosterone/GH), leading to potential loss of lean mass and strength over time.

Prioritize 7-9 hours of sleep nightly to protect muscle mass. Sleep loss directly reduces your body's ability to build muscle (protein synthesis) and shifts hormones toward breaking it down (catabolism). If you are training hard, poor sleep undermines your gains more than you might think. Consistency in sleep duration is as important as consistency in training.

GLP-1 receptor agonists (specifically Liraglutide 3.0mg and Semaglutide 2.4mg) significantly reduce the incidence of type 2 diabetes in obese individuals with prediabetes, often outperforming placebo and sometimes matching or exceeding lifestyle interventions.

If you are obese and have prediabetes, ask your doctor about GLP-1 medications like Semaglutide or Liraglutide. They are highly effective at preventing diabetes, often working better than diet and exercise alone because they help control appetite and blood sugar automatically.

Triple incretin agonists (GLP-1R/GIPR/GCGR) produce superior body weight reduction (up to 24.2%) compared to dual or mono-agonists, approaching the efficacy of bariatric surgery.

Retatrutide, a once-weekly injection targeting three gut hormone receptors, has shown remarkable weight loss results (up to 24% in trials). While side effects like nausea are common, they are often manageable by starting with a lower dose. This therapy represents a significant advancement over older GLP-1 drugs, offering efficacy closer to bariatric surgery without the surgical risks.

GLP-1/Glucagon dual agonists (e.g., mazdutide, survodutide) produce greater weight loss and triglyceride reduction compared to GLP-1 mono-agonists.

Dual agonists targeting GLP-1 and Glucagon receptors (like survodutide) have shown significant weight loss (up to 18.7%) and improved triglyceride levels in Phase 2 trials. These drugs leverage the fat-burning and energy-expenditure effects of glucagon while maintaining glucose control through GLP-1.

GLP-1 receptor agonists (e.g., liraglutide) produce significant weight loss (mean 8.4 kg over 56 weeks) by slowing gastric emptying and activating central satiety pathways, with 33.1% of patients achieving >10% body weight loss.

If you have obesity (BMI > 30, or > 27 with health issues), ask your doctor about GLP-1 agonists like liraglutide. This medication, taken daily, has been shown in clinical trials to help patients lose an average of 8.4 kg over a year, with many losing over 10% of their body weight. It works by slowing digestion and signaling fullness to your brain.

GLP-1 receptor agonists (semaglutide 2.4 mg/week and liraglutide 3 mg/day) produce significant weight loss in adults with obesity or overweight with comorbidities by delaying gastric emptying and increasing satiety, with semaglutide demonstrating superior efficacy compared to liraglutide.

If you have obesity or overweight with a related health condition, ask your doctor about GLP-1 agonists like semaglutide. They are taken as a once-weekly injection and work by making you feel full and slowing digestion. They are most effective when combined with a reduced-calorie diet and increased physical activity.